CoChat

The Potential of Pregabalin in Neurology, Psychiatry and Addiction: A Qualitative Overview

Martinotti, Giovanni, Lupi, Matteo, Sarchione, Fabiola, Santacroce, Rita, Salone, Anatolia, Berardis, Domenico, Serroni, Nicola, Cavuto, Marilde, Signorelli, Maria, Aguglia, Eugenio, Valchera, Alessandro, Iasevoli, Felice, Giannantonio, Massimo · 2013 · Current Pharmaceutical Design
Cited by 72

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Pregabalin is an anticonvulsant drug that binds to the α₂δ (alpha2delta) subunit of the voltage-dependent calcium channel in central nervous system (CNS). Pregabalin decreases the release of neurotransmitters, including glutamate, norepinephrine, substance P and calcitonin gene-related peptide. Purpose of this paper is to offer a qualitative overview of the studies currently available in literature about this drug, examining the effectiveness of pregabalin in its various fields of application. Our analysis, conducted on a final selection of 349 scientific papers, shows that pregabalin may help to reduce pain in diabetic neuropathy, in post-herpetic neuralgia and in some patients affected by fibromyalgia. It is also effective for the treatment of diverse types of seizures and has similar efficacy to benzodiazepines and venlafaxine in anxiety disorder. Moreover, pregabalin may be a therapeutic agent for the treatment of alcohol abuse, in both withdrawal phase and relapse prevention. Possible implications in the treatment of benzodiazepines dependence are emerging, but a potential abuse or misuse of the drug has also been reported. Range of dosage may fluctuate considerably, from 75 mg to 600 mg per day. Further studies are needed to completely understand pregabalin mechanism of action in the different diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/13816128113199990425

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Metadata

Authors
Martinotti, G., Lupi, M., Sarchione, F., Santacroce, R., Salone, A., Berardis, D., Serroni, N., Cavuto, M., Signorelli, M., Aguglia, E., Valchera, A., Iasevoli, F., & Giannantonio, M.
Venue
Current Pharmaceutical Design
Published
2013-09-01
Volume
19
Issue
35
Pages
6367-6374
ISSN
1381-6128 (ISSN-L)
OpenAlex
W1992366653
Cited by
72
References
8
FWCI
4.90
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Potential of Pregabalin in Neurology, Psychiatry and Addiction: A Qualitative Overview. https://app.cochat.ai/papers/10.2174/13816128113199990425
The paper
Martinotti, G., Lupi, M., Sarchione, F., Santacroce, R., Salone, A., Berardis, D., Serroni, N., Cavuto, M., Signorelli, M., Aguglia, E., Valchera, A., Iasevoli, F., & Giannantonio, M. (2013). The Potential of Pregabalin in Neurology, Psychiatry and Addiction: A Qualitative Overview. Current Pharmaceutical Design. https://doi.org/10.2174/13816128113199990425

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.